頭頸癌治療市場：按產品（博萊黴素、西妥昔單抗、多西他賽）、按藥物類別（化療​​、免疫療法、放射線治療）、最終用戶 - 2023 年至 2030 年全球預測

預計2023年全球頭頸癌治療市場將達13.5641億美元，複合年成長率為15.41%，預計2030年將達37.0386億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球頭頸癌治療市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球頭頸癌治療藥物市場規模及預測為何？

2.在預測期內，COVID-19 對全球頭頸癌治療藥物市場的阻礙因素與影響為何？

3.在預測期內，全球頭頸癌藥物市場應投資哪些產品/細分市場/用途/領域？

4.你們在全球頭頸癌藥物市場的競爭策略是什麼？

5.全球頭頸癌藥物市場的技術趨勢和法律規範是什麼？

6.全球頭頸癌治療藥物市場主要廠商的市佔率為何？

7. 哪些型態和策略性措施被認為適合進入全球頭頸癌藥物市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 全球頭頸癌發生率上升
    • 增加政府和私營部門對癌症治療的配合措施
    • 頭頸癌藥物的核准增加
  • 抑制因素
    • 藥品很貴
  • 機會
    • 頭頸癌藥物的優惠報銷
    • 後期管道藥物開發的新投資
  • 任務
    • 與藥物攝取相關的副作用
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化

第6章 頭頸癌治療市場：按產品

• 介紹
• 博來黴素
• 西妥昔單抗
• 多西紫杉醇
• 愛必妥（西妥昔單抗）
• Hydrea（羥基脲）
• 羥基脲
• Keytruda（派姆單抗）
• 甲胺蝶呤
• 納武單抗
• Opdivo（納武單抗）
• 帕博利珠單抗
• 泰索帝（多西紫杉醇）
• Trexol（甲胺蝶呤）

第7章 頭頸癌治療藥物市場：依藥效分類

• 介紹
• 化學處理
• 免疫療法
• 放射治療
• 外科手術
• 標靶治療

第8章 頭頸癌藥物市場：依最終用戶分類

• 介紹
• 癌症研究
• 診所
• 醫院

第9章 北美和南美頭頸癌藥物市場

• 介紹
• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第10章 亞太地區頭頸癌藥物市場

• 介紹
• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第11章歐洲、中東和非洲頭頸癌藥物市場

• 介紹
• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第12章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第13章上市公司名單

第14章附錄

• 討論指南
• 關於許可證和定價

The Global Head & Neck Cancer Drugs Market is forecasted to grow significantly, with a projected USD 1,356.41 million in 2023 at a CAGR of 15.41% and expected to reach a staggering USD 3,703.86 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Head & Neck Cancer Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Head & Neck Cancer Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Bleomycin, Cetuximab, Docetaxel, Erbitux (Cetuximab), Hydrea (Hydroxyurea), Hydroxyurea, Keytruda (Pembrolizumab), Methotrexate, Nivolumab, Opdivo (Nivolumab), Pembrolizumab, Taxotere (Docetaxel), and Trexall (Methotrexate). The Trexall (Methotrexate) is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Chemotherapy, Immunotherapy, Radiation therapy, Surgery, and Targeted Therapy. The Radiation therapy is projected to witness significant market share during forecast period.

Based on End User, market is studied across Cancer Research Institutes, Clinics, and Hospitals. The Cancer Research Institutes is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Head & Neck Cancer Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Head & Neck Cancer Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Head & Neck Cancer Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Head & Neck Cancer Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Head & Neck Cancer Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Head & Neck Cancer Drugs Market?

6. What is the market share of the leading vendors in the Global Head & Neck Cancer Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Head & Neck Cancer Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Head & Neck Cancer Drugs Market, by Product, 2022 vs 2030
• 4.3. Head & Neck Cancer Drugs Market, by Drug Class, 2022 vs 2030
• 4.4. Head & Neck Cancer Drugs Market, by End User, 2022 vs 2030
• 4.5. Head & Neck Cancer Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of head and neck cancer all across the globe
    • 5.1.1.2. Rise in government and private body initiatives for cancer treatment
    • 5.1.1.3. Increased approval for head & neck cancer drugs
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of the drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Favorable reimbursements for head and neck cancer drugs
    • 5.1.3.2. New investments for developing late-stage pipeline drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effect associated with the consumption of the drug
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Head & Neck Cancer Drugs Market, by Product

• 6.1. Introduction
• 6.2. Bleomycin
• 6.3. Cetuximab
• 6.4. Docetaxel
• 6.5. Erbitux (Cetuximab)
• 6.6. Hydrea (Hydroxyurea)
• 6.7. Hydroxyurea
• 6.8. Keytruda (Pembrolizumab)
• 6.9. Methotrexate
• 6.10. Nivolumab
• 6.11. Opdivo (Nivolumab)
• 6.12. Pembrolizumab
• 6.13. Taxotere (Docetaxel)
• 6.14. Trexall (Methotrexate)

7. Head & Neck Cancer Drugs Market, by Drug Class

• 7.1. Introduction
• 7.2. Chemotherapy
• 7.3. Immunotherapy
• 7.4. Radiation therapy
• 7.5. Surgery
• 7.6. Targeted Therapy

8. Head & Neck Cancer Drugs Market, by End User

• 8.1. Introduction
• 8.2. Cancer Research Institutes
• 8.3. Clinics
• 8.4. Hospitals

9. Americas Head & Neck Cancer Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Head & Neck Cancer Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Head & Neck Cancer Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. HEAD & NECK CANCER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. HEAD & NECK CANCER DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
• FIGURE 5. HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 6. HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2022 VS 2030 (%)
• FIGURE 7. HEAD & NECK CANCER DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. HEAD & NECK CANCER DRUGS MARKET DYNAMICS
• FIGURE 9. HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. HEAD & NECK CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. HEAD & NECK CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. HEAD & NECK CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 5. HEAD & NECK CANCER DRUGS MARKET SIZE, BY BLEOMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. HEAD & NECK CANCER DRUGS MARKET SIZE, BY CETUXIMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. HEAD & NECK CANCER DRUGS MARKET SIZE, BY DOCETAXEL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. HEAD & NECK CANCER DRUGS MARKET SIZE, BY ERBITUX (CETUXIMAB), BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDREA (HYDROXYUREA), BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDROXYUREA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. HEAD & NECK CANCER DRUGS MARKET SIZE, BY KEYTRUDA (PEMBROLIZUMAB), BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. HEAD & NECK CANCER DRUGS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. HEAD & NECK CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. HEAD & NECK CANCER DRUGS MARKET SIZE, BY OPDIVO (NIVOLUMAB), BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. HEAD & NECK CANCER DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. HEAD & NECK CANCER DRUGS MARKET SIZE, BY TAXOTERE (DOCETAXEL), BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. HEAD & NECK CANCER DRUGS MARKET SIZE, BY TREXALL (METHOTREXATE), BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 19. HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. HEAD & NECK CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. HEAD & NECK CANCER DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. HEAD & NECK CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. HEAD & NECK CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 60. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 62. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 63. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 68. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 75. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 84. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 100. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 105. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 108. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 109. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 111. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 112. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 113. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 115. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 117. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 118. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 121. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 123. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 124. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 127. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 129. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 130. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 133. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 135. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 136. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 138. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 142. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 144. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 145. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 147. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 148. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 149. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 150. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 151. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 152. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 153. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 154. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 155. HEAD & NECK CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 156. HEAD & NECK CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 157. HEAD & NECK CANCER DRUGS MARKET LICENSE & PRICING